

JUSTIFICATION FOR SINGLE SOURCE AWARDS IAW FAR 13.106-1
(OVER MICRO-PURCHASE THRESHOLD(\$3K) BUT NOT EXCEEDING THE SAT (\$150K))

IAW [FAR13.104](#), COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW [FAR13.106-1\(b\)](#), COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW [FAR13.106-3\(b\)\(3\)](#), COs are required to include additional statements ***explaining the absence of competition*** (see [13.106-1](#) for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW [FAR13.106-3\(b\)\(3\)](#). Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

1. PURCHASE REQUEST OR REQUISITION NUMBER:

766-17-4-400-0721

**1A. PROJECT/TASK
NUMBER**

N/A

1B. ESTIMATED AMOUNT:

\$

2. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES REQUIRED AND THE INTENDED USE:

PARKIND PRODUCTS

1. Treatment of Parkinson's disease and syndrome medication

CARBIDOPA 25/LEVODOPA 100MG SA TAB (C0620)

NDC- 62756-0461-88

Quantity: 1,440

Manufacturer: Sun Pharmaceuticals

3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO ONLY ONE SOURCE, WITH THE REASON NO OTHER SUPPLIES OR SERVICES CAN BE USED:

Within the VHA brand name items may be prescribed by physicians when in their clinical judgment the brand name item will provide a better therapeutic outcome for patients. The brand name of the product is in the CMOP print name. Pharmacists legally have to fill the prescription as it was written.

4. REASON THAT SUGGESTED SOURCE IS THE ONLY SOURCE, WHICH CAN PROVIDE THE SUPPLIES OR SERVICES:

This is available through multiple sources on the open market but there is only one manufacturer of this medication per physician prescriptions only Brand Name is acceptable.

Carbidopa and levodopa extended-release tablets are extended-release combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome.

5. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED:

NAC FSS AND GSA ADVANTAGE WERE SEARCHED AND NO CONTRACT ITEMS WERE FOUND.

6. Contracting Officer's Certification: *Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief.*

Signature: _____

Date: _____

Name: _____

Title: _____

Facility: _____